Policicchio, Benjamin BrunoSette, PaolaXu, CuilingHaret-Richter, GeorgeDunsmore, TammyPandrea, IvonaRibeiro, Ruy M.Apetrei, Cristian2020-12-032020-12-032018PLoS ONE 13(2): e0190908.http://hdl.handle.net/10451/45119Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.Two SIVmac251-infected rhesus macaques received tenofovir/emtricitabine with raltegravir intensification. Viral rebound occurred during treatment and sequencing of reverse transcriptase and integrase genes identified multiple resistance mutations. Similar to HIV infection, antiretroviral-resistance mutations may occur in SIV-infected nonhuman primates receiving nonsuppressive ART. As ART administration to nonhuman primates is currently dramatically expanding, fueled by both cure research and the study of HIV-related comorbidities, viral resistance should be factored in the study design and data interpretation.engjournal article10.1371/journal.pone.01909081932-6203